NCT03588546Completed
FASENRA SCEI for Long-term Use
FASENRA Subcutaneous Injection 30 mg Syringe Specific Clinical Experience Investigation for Long-term Use
Source: ClinicalTrials.gov · Last updated 2 Sept 2025
Brief summary (registry, in English)
The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 653 (actual)
- First submitted
- 25 May 2018
- Start date
- 31 May 2018
- Primary completion date
- 10 Sept 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT03588546
What you commit to
- Study type: Observational
- Participants enrolled: 653
- From 31 May 2018 to the primary completion date, 10 Sept 2024
- 29 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- -No past history of hypersensitivity to the components of Fasenra.
Who the study is looking for
- -The evaluable patients treated with Fasenra for the first time due to "Bronchial asthma (only the patients with intractable bronchial asthma which could not be controlled with the existing therapy).
Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.